3 models fit InMode Ltd. Ordinary Shares and they disagree: 1 of 3 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Gold84
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionInMode Ltd. Ordinary Shares (INMD)
Fair value (3 models)
$45.27
ACCE price target
$14.20
Rating
Undervalued
Horizon
12 months
Fair value published on 25 Oct 2026, 17:04 CET; previously $35.48 since 18 Oct 2026, 15:06 CEST.
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Rating published on 18 Oct 2026, 15:06 CEST.
Price used: $13.97 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
69.1% below
+224.1% to fair value
ACCE score
56
out of 100
Analysts
0% buy
5 covering
P/E
11.6x
forward 8.7x
1-year return
-9.8%
Dividend yield
0.00%
InMode Ltd. Ordinary Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
InMode makes radiofrequency and energy-based aesthetic and surgical devices, including the Morpheus8 and Evolve platforms, sold to dermatologists, plastic surgeons and gynecologists largely on a capital-equipment model with recurring disposables. Its moat rests on a 76.5% gross margin, which points to pricing power and a consumables stream that competitors struggle to replicate on the same installed base. At 10.0x forward earnings and an 11.8x trailing multiple, with a 12.8% operating margin and a 12.3% ROE, the stock prices in little growth. The reported 0.0% revenue growth is the central question, so a deeper look should establish whether that flat line reflects a cyclical pause in aesthetic capital spending or a maturing product cycle. Given the score of 58/100 and no index membership, this is a candidate for diligence, not a conclusion.